A large spectrum of avian influenza virus to which the human population is naTve is present in wild aquatic birds, and highly pathogenic H5N1 avian strains are currently circulating in several countries in southeast Asia where they have caused dozens of human fatalities. These strains are of particular concern because they are resistant to the most cost-effective antiviral drugs, amantadine and rimantadine. The emergence of a novel transmissible influenza virus against which the population has little or no immunity would cause a global pandemic, for which no vaccine is available. Current influenza vaccines are produced from viruses that are adapted to grow well in embryonated hens'eggs, whereas highly pathogenic avian influenza viruses are lethal for hens'eggs, making the current methods of vaccine production problematic. Alternative approaches to develop effective influenza vaccines are therefore urgently needed. In an effort to develop alternatives for influenza vaccine production and in response to a pandemic threat, our goal in this project is to determine whether influenza virus-like particle based vaccines will provide protective immunity against a highly pathogenic avian influenza virus. Additional goals are to address other shortcomings of current influenza vaccines: they exhibit limited efficacy, they fail to protect against infection at mucosal surfaces, and the observed immunity is highly strain-specific and of short duration. Thus, we will develop approaches to enhance the immunogenicity of influenza vaccines, to enhance memory responses to the vaccine, and to induce effective immune responses at mucosal surfaces which may be protective against a broader range of viral strains. In addition to a panel of assays to monitor humoral and cellular immune responses, we will make use of novel transgenic mice which have been constructed to directly measure the magnitude of B cell memory generated in response to immunization.
The specific aims of the project are:1. to produce virus-like particles (VLPs) incorporating influenza viral glycoproteins and matrix (M1) protein;2. to characterize humoral and cellular immune responses after immunization with influenza VLPs and their protective efficacy; and 3. to develop more effective influenza VLP-based vaccines by incorporation of ligands designed to target the VLPs to antigen-presenting cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI068003-05
Application #
7759552
Study Section
Special Emphasis Panel (ZRG1-VMD (01))
Program Officer
Salomon, Rachelle
Project Start
2006-02-15
Project End
2013-01-31
Budget Start
2010-02-01
Budget End
2013-01-31
Support Year
5
Fiscal Year
2010
Total Cost
$517,585
Indirect Cost
Name
Emory University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Wang, Li; Hess, Annie; Chang, Timothy Z et al. (2014) Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines. Nanomedicine 10:473-82
Wang, Bao-Zhong; Gill, Harvinder S; He, Cheng et al. (2014) Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. J Control Release 178:1-7
Kim, Yeu-Chun; Yoo, Dae-Goon; Compans, Richard W et al. (2013) Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J Control Release 172:579-88
Wang, Li; Wang, Ying-Chun; Feng, Hao et al. (2013) Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice. Biomed Res Int 2013:686549
Quan, Fu-Shi; Kim, Yeu-Chun; Song, Jae-Min et al. (2013) Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch. Clin Vaccine Immunol 20:1433-9
Wang, Bao-Zhong; Gill, Harvinder S; Kang, Sang-Moo et al. (2012) Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand. Clin Vaccine Immunol 19:1119-25
Quan, Fu-Shi; Li, Zhu-Nan; Kim, Min-Chul et al. (2011) Immunogenicity of low-pH treated whole viral influenza vaccine. Virology 417:196-202
Kang, S M; Song, J M; Compans, R W (2011) Novel vaccines against influenza viruses. Virus Res 162:31-8
Kim, Yeu-Chun; Quan, Fu-Shi; Compans, Richard W et al. (2011) Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm Res 28:135-44
Song, Jae-Min; Choi, Chi-Won; Kwon, Sang-Oh et al. (2011) Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity. J Proteome Res 10:3450-9

Showing the most recent 10 out of 24 publications